Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Sells $1,024,465.11 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTXGet Free Report) CEO Eric M. Dube sold 50,691 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $20.21, for a total value of $1,024,465.11. Following the completion of the transaction, the chief executive officer now directly owns 430,548 shares of the company’s stock, valued at approximately $8,701,375.08. This trade represents a 10.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $21.10 on Wednesday. The business has a 50-day moving average of $18.69 and a two-hundred day moving average of $15.47. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $21.56.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TVTX. Cantor Fitzgerald began coverage on shares of Travere Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating for the company. Leerink Partners reissued an “outperform” rating and issued a $20.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, October 8th. Wedbush upped their price objective on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. HC Wainwright lifted their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Finally, Guggenheim increased their price target on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

View Our Latest Report on Travere Therapeutics

Institutional Trading of Travere Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd purchased a new stake in shares of Travere Therapeutics in the fourth quarter worth about $53,000. CWM LLC lifted its position in Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after acquiring an additional 3,065 shares in the last quarter. Quarry LP purchased a new position in Travere Therapeutics in the 3rd quarter worth approximately $105,000. Sei Investments Co. acquired a new stake in Travere Therapeutics in the second quarter valued at approximately $117,000. Finally, Diversified Trust Co purchased a new stake in shares of Travere Therapeutics during the third quarter valued at approximately $161,000.

Travere Therapeutics Company Profile

(Get Free Report)

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Further Reading

Insider Buying and Selling by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.